Publications

  1. Murthy V, Gao Y, Geng L, LeBrasseur NK, White TA, Parks RJ, Brimijoin S. Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice. Vaccine. 2014 Jul 16; 32(33):4155-62. Epub 2014 Jun 02.
    View PubMed
  2. Murthy V, Gao Y, Geng L, LeBrasseur N, White T, Brimijoin S. Preclinical studies on neurobehavioral and neuromuscular effects of cocaine hydrolase gene therapy in mice. J Mol Neurosci. 2014 Jul; 53(3):409-16. Epub 2013 Oct 02.
    View PubMed
  3. Zlebnik NE, Brimijoin S, Gao Y, Saykao AT, Parks RJ, Carroll ME. Long-term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity. Neuropsychopharmacology. 2014 May; 39(6):1538-46. Epub 2014 Jan 10.
    View PubMed
  4. Larrimore KE, Barcus M, Kannan L, Gao Y, Zhan CG, Brimijoin S, Mor T. Plants as a source of butyrylcholinesterase variants designed for enhanced cocaine hydrolase activity. Chem Biol Interact. 2013 Mar 25; 203(1):217-20. Epub 2012 Sep 20.
    View PubMed
  5. Brimijoin S, Shen X, Orson F, Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines. 2013 Mar; 12(3):323-32.
    View PubMed
  6. Gao J, Li Y, Zhu N, Brimijoin S, Sui N. Roles of dopaminergic innervation of nucleus accumbens shell and dorsolateral caudate-putamen in cue-induced morphine seeking after prolonged abstinence and the underlying D1- and D2-like receptor mechanisms in rats. J Psychopharmacol. 2013 Feb; 27(2):181-91. Epub 2012 Nov 13.
    View PubMed
  7. Geng L, Gao Y, Chen X, Hou S, Zhan CG, Radic Z, Parks RJ, Russell SJ, Pham L, Brimijoin S. Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS One. 2013; 8(6):e67446. Epub 2013 Jun 28.
    View PubMed
  8. Anker JJ, Brimijoin S, Gao Y, Geng L, Zlebnik NE, Parks RJ, Carroll ME. Cocaine hydrolase encoded in viral vector blocks the reinstatement of cocaine seeking in rats for 6 months. Biol Psychiatry. 2012 Apr 15; 71(8):700-5. Epub 2011 Dec 30.
    View PubMed
  9. Seo S, Lomberk G, Mathison A, Buttar N, Podratz J, Calvo E, Iovanna J, Brimijoin S, Windebank A, Urrutia R. Kruppel-like factor 11 differentially couples to histone acetyltransferase and histone methyltransferase chromatin remodeling pathways to transcriptionally regulate dopamine D2 receptor in neuronal cells. J Biol Chem. 2012 Apr 13; 287(16):12723-35. Epub 2012 Feb 28.
    View PubMed
  10. Pang YP, Brimijoin S, Ragsdale DW, Zhu KY, Suranyi R. Novel and viable acetylcholinesterase target site for developing effective and environmentally safe insecticides. Curr Drug Targets. 2012 Apr; 13(4):471-82.
    View PubMed
  11. Brimijoin S, Gao Y. Cocaine hydrolase gene therapy for cocaine abuse. Future Med Chem. 2012 Feb; 4(2):151-62.
    View PubMed
  12. Brimijoin S. Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users. CNS Neurol Disord Drug Targets. 2011 Dec; 10(8):880-91.
    View PubMed
  13. Carroll ME, Gao Y, Brimijoin S, Anker JJ. Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology (Berl). 2011 Feb; 213(4):817-29.
  14. Polsinelli GA, Singh SK, Mishra RK, Suranyi R, Ragsdale DW, Pang YP, Brimijoin S. Insect-specific irreversible inhibitors of acetylcholinesterase in pests including the bed bug, the eastern yellowjacket, German and American cockroaches, and the confused flour beetle. Chem Biol Interact. 2010 Sep 6; 187(1-3):142-7. Epub 2010 Jan 28.
    View PubMed
  15. Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S. The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem Biol Interact. 2010 Sep 6; 187(1-3):421-4. Epub 2010 Feb 26.
    View PubMed
  16. Gao Y, Brimijoin S. Lasting reduction of cocaine action in neostriatum--a hydrolase gene therapy approach. J Pharmacol Exp Ther. 2009 Aug; 330(2):449-57. Epub 2009 May 28.
    View PubMed
  17. Ray A, Liu J, Karanth S, Gao Y, Brimijoin S, Pope C. Cholinesterase inhibition and acetylcholine accumulation following intracerebral administration of paraoxon in rats. Toxicol Appl Pharmacol. 2009 May 1; 236(3):341-7. Epub 2009 Mar 06.
    View PubMed
  18. Tang H, Pavel J, Saavedra JM, Brimijoin S. Type-1 angiotensin receptors are expressed and transported in motor and sensory axons of rat sciatic nerves. Neuropeptides. 2009 Apr; 43(2):81-92. Epub 2009 Feb 23.
    View PubMed
  19. Pang YP, Ekstrom F, Polsinelli GA, Gao Y, Rana S, Hua DH, Andersson B, Andersson PO, Peng L, Singh SK, Mishra RK, Zhu KY, Fallon AM, Ragsdale DW, Brimijoin S. Selective and irreversible inhibitors of mosquito acetylcholinesterases for controlling malaria and other mosquito-borne diseases. PLoS One. 2009; 4(8):e6851. Epub 2009 Aug 28.
    View PubMed
  20. Pang YP, Singh SK, Gao Y, Lassiter TL, Mishra RK, Zhu KY, Brimijoin S. Selective and irreversible inhibitors of aphid acetylcholinesterases: steps toward human-safe insecticides. PLoS One. 2009; 4(2):e4349. Epub 2009 Feb 04.
    View PubMed
  21. Hu W, Gray NW, Brimijoin S. Amyloid-beta alters trafficking of internalized acetylcholinesterase and dextran. International Journal of Physiology, Pathophysiology and Pharmacology. 2009; 1(1):15-24.
    View PubMed
  22. Pavel J, Tang H, Brimijoin S, Moughamian A, Nishioku T, Benicky J, Saavedra JM. Expression and transport of Angiotensin II AT1 receptors in spinal cord, dorsal root ganglia and sciatic nerve of the rat. Brain Res. 2008 Dec 30; 1246:111-22. Epub 2008 Oct 17.
    View PubMed
  23. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R, Zhao Q, Singh M, Carroll ME. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology. 2008 Oct; 33(11):2715-25. Epub 2008 Jan 16.
    View PubMed
  24. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, Brimijoin S. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact. 2008 Sep 25; 175(1-3):83-7. Epub 2008 May 01.
    View PubMed
  25. Tang H, Pavel J, Saavedra JM, Brimijoin S. Angiotensin II type 1 receptors may not influence response of spinal autonomic neurons to axonal damage. Neurol Res. 2008 Sep; 30(7):751-60. Epub 2008 May 21.
    View PubMed
  26. Lassiter TL, Brimijoin S. Rats gain excess weight after developmental exposure to the organophosphorothionate pesticide, chlorpyrifos. Neurotoxicol Teratol. 2008 Mar-Apr; 30(2):125-30. Epub 2007 Nov 06.
    View PubMed
  27. Brimijoin S. Neuroscience in China. Cell Mol Neurobiol. 2008 Jan; 28(1):1-2. Epub 2007 Nov 14.
    View PubMed
  28. Garcia-Ayllon MS, Silveyra MX, Andreasen N, Brimijoin S, Blennow K, Saez-Valero J. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. J Neurochem. 2007 Jun; 101(6):1701-11. Epub 2007 Feb 26.
    View PubMed
  29. Lassiter TL, Brimijoin S. A method to determine precise benchmark doses for carbamate anticholinesterases. Toxicol Sci. 2007 Mar; 96(1):154-61. Epub 2006 Dec 11.
    View PubMed
  30. Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis. 2006 Nov; 24(2):326-33. Epub 2006 Sep 14.
    View PubMed
  31. Gao Y, Brimijoin S. Viral transduction of cocaine hydrolase in brain reward centers. Cell Mol Neurobiol. 2006 Jul-Aug; 26(4-6):357-63. Epub 2006 May 18.
    View PubMed
  32. Gao Y, Brimijoin S. Visualizing viral transduction of a cocaine-hydrolyzing, human butyrylcholinesterase in rats. Chem Biol Interact. 2005 Dec 15; 157-158:97-103. Epub 2005 Oct 21.
    View PubMed
  33. Rees TM, Berson A, Sklan EH, Younkin L, Younkin S, Brimijoin S, Soreq H. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr Alzheimer Res. 2005 Jul; 2(3):291-300.
    View PubMed
  34. Brimijoin S. Can cholinesterase inhibitors affect neural development? Environ Toxicol Pharmacol. 2005 May; 19(3):429-32. Epub 2005 Feb 12.
    View PubMed
  35. Gao Y, Atanasova E, Sui N, Pancook JD, Watkins JD, Brimijoin S. Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol Pharmacol. 2005 Jan; 67(1):204-11. Epub 2004 Oct 01.
    View PubMed
  36. Gao Y, Brimijoin S. An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Exp Ther. 2004 Sep; 310(3):1046-52. Epub 2004 Apr 20.
    View PubMed
  37. Conti AM, Brimijoin S, Miller LJ, Windebank AJ. Suppression of neurite outgrowth by high-dose nerve growth factor is independent of functional p75NTR receptors. Neurobiol Dis. 2004 Feb; 15(1):106-14.
    View PubMed
  38. Hammond PI, Kern C, Hong F, Kollmeyer TM, Pang YP, Brimijoin S. Cholinesterase reactivation in vivo with a novel bis-oxime optimized by computer-aided design. J Pharmacol Exp Ther. 2003 Oct 1; 307(1):190-6.
    View PubMed
  39. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging. 2003 Oct; 24(6):777-87.
    View PubMed
  40. Hu W, Gray NW, Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J Neurochem. 2003 Jul; 86(2):470-8.
    View PubMed
  41. Pang YP, Kollmeyer TM, Hong F, Lee JC, Hammond PI, Haugabouk SP, Brimijoin S. Rational design of alkylene-linked bis-pyridiniumalidoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun; 10(6):491-502.
    View PubMed
  42. Leelakusolvong S, Bharucha AE, Sarr MG, Hammond PI, Brimijoin S, Phillips SF. Effect of extrinsic denervation on muscarinic neurotransmission in the canine ileocolonic region. Neurogastroenterol Motil. 2003 Apr; 15(2):173-86.
    View PubMed
  43. Hammond PI, Craig TA, Kumar R, Brimijoin S. Regional and cellular distribution of DREAM in adult rat brain consistent with multiple sensory processing roles. Brain Res Mol Brain Res. 2003 Mar 17; 111(1-2):104-10.
    View PubMed
  44. Rees TM, Brimijoin S. The role of acetylicholinesterase in the pathogenesis of Alzheimer's disease. Drugs of Today. 2003 Jan; 39(1):75-83.
    View PubMed
  45. Zhang H, Brimijoin S, Tang X-C. Apoptosis by β-amyloid25-35 in acetylcholine-esterase-overexpressing neuroblastoma cells. Acta Pharmacol Sinica. 2003; 24:853-858.
  46. Brimijoin S, Shen ML, Sun H. Radiometric solvent-partitioning assay for screening cocaine hydrolases and measuring cocaine levels in milligram tissue samples. Anal Biochem. 2002 Oct 15; 309(2):200-5.
    View PubMed
  47. Tang H, Brimijoin S. Death of preganglionic sympathetic neurons after surgical or immunologic lesion of peripheral processes. Exp Neurol. 2002 Sep; 177(1):105-14.
    View PubMed
  48. Sun H, Pang YP, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol. 2002 Aug; 62(2):220-4.
    View PubMed
  49. Sun H, Shen ML, Pang YP, Lockridge O, Brimijoin S. Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J Pharmacol Exp Ther. 2002 Aug; 302(2):710-6.
    View PubMed
  50. Tang H, Brimijoin S. Complement regulatory proteins and selective vulnerability of neurons to lysis on exposure to acetylcholinesterase antibody. J Neuroimmunol. 2001 Apr 2; 115(1-2):53-63.
    View PubMed
  51. Sun H, El Yazal J, Lockridge O, Schopfer LM, Brimijoin S, Pang YP. Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase. Engineering effective butyrylcholinesterase mutants for cocaine detoxication. J Biol Chem. 2001 Mar 23; 276(12):9330-6. Epub 2000 Dec 04.
    View PubMed
  52. Sharma KV, Brimijoin S, Koenigsberger C, Bigbee J. Acetylcholinesterase modulates the adhesion of neuroblastoma cells. J Neurosci Res , 2001; 63:165-175.
  53. Li B, Stribley JA, Ticu A, Xie W, Schopfer LM, Hammond P, Brimijoin S, Hinrichs S, Lockridge O. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J. Neurochem. 2001; 75:1320-1331.
  54. Atanasova E, Chiappa S, Wieben E, Brimijoin S. Novel messenger RNA and alternative promoter for murine acetylcholinesterase. J Biol Chem. 1999 Jul 23; 274(30):21078-84.
    View PubMed
  55. Tang H, Miller SM, Ermilov LG, Lennon VA, Brimijoin S. Complement-mediated lesion of sympathetic ganglia in vitro with acetylcholinesterase antibodies. J Neuroimmunol. 1999 Jun 1; 97(1-2):86-93.
    View PubMed
  56. Brimijoin S, Koenigsberger C. Cholinesterases in neural development: new findings and toxicologic implications. Environ Health Perspect. 1999 Feb; 107 Suppl 1:59-64.
    View PubMed
  57. Veenstra TD, Prufer K, Koenigsberger C, Brimijoin SW, Grande JP, Kumar R. 1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo. Brain Res. 1998 Sep 7; 804(2):193-205.
    View PubMed
  58. Pang YP, Brimijoin S. Supercomputing-based dimeric analog approach for drug optimization. Parallel Comput. 1998 Sep; 24(9-10):1557-1566.
  59. Tang H, Hammond P, Brimijoin S. Acetylcholinesterase immunolesioning: regional vulnerability of preganglionic sympathetic neurons in rat spinal cord. Exp Neurol. 1998 Aug; 152(2):167-76.
    View PubMed
  60. Koenigsberger C, Hammond P, Brimijoin S. Developmental expression of acetyl- and butyrylcholinesterase in the rat: enzyme and mRNA levels in embryonic dorsal root ganglia. Brain Res. 1998 Mar 23; 787(2):248-58.
    View PubMed
  61. Mortensen SR, Brimijoin S, Hooper MJ, Padilla S. Comparison of the in vitro sensitivity of rat acetylcholinesterase to chlorpyrifos-oxon: what do tissue IC50 values represent? Toxicol Appl Pharmacol. 1998 Jan; 148(1):46-9.
    View PubMed
  62. Miller SM, Ermilov LG, Szurszewski JH, Hammond PI, Brimijoin S. Selective disruption of neurotransmission by acetylcholinesterase antibodies in sympathetic ganglia examined with intracellular microelectrodes. J Auton Nerv Syst. 1997 Dec 11; 67(3):156-67.
    View PubMed
  63. Koenigsberger C, Chiappa S, Brimijoin S. Neurite differentiation is modulated in neuroblastoma cells engineered for altered acetylcholinesterase expression. J Neurochem. 1997 Oct; 69(4):1389-97.
    View PubMed
  64. Veenstra TD, Londowski JM, Windebank AJ, Brimijoin S, Kumar R. Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells. Brain Res Dev Brain Res. 1997 Mar 17; 99(1):53-60.
    View PubMed
  65. Pang YP, Hong F, Quiram P, Jelacic T, Brimijoin S. Synthesis of alkylene linked bis-THA and alkylene linked benzyl-THA as highly potent and selective inhibitors and molecular probes of acetylcholinesterase. J Chem Soc Perkin Trans. 1997 Jan 21(2):171-6.
  66. Holgert H, Holmberg K, Hannibal J, Fahrenkrug J, Brimijoin S, Hartman BK, Hokfelt T. PACAP in the adrenal gland--relationship with choline acetyltransferase, enkephalin and chromaffin cells and effects of immunological sympathectomy. Neuroreport. 1996 Dec 20; 8(1):297-301.
    View PubMed
  67. Holgert H, Lagercrantz H, Dagerlind A, Hartman BK, Cozzari C, Brimijoin S, Hokfelt T. Effects of immunological sympathectomy on postnatal peptide expression in the rat adrenal medulla. Brain Res Dev Brain Res. 1996 Nov 22; 97(1):88-95.
    View PubMed
  68. Hammond PI, Jelacic T, Padilla S, Brimijoin S. Quantitative, video-based histochemistry to measure regional effects of anticholinesterase pesticides in rat brain. Anal Biochem. 1996 Oct 1; 241(1):82-92.
    View PubMed
  69. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J Biol Chem. 1996 Sep 27; 271(39):23646-9.
    View PubMed
  70. Wilson BW, Padilla S, Henderson JD, Brimijoin S, Dass PD, Elliot G, Jaeger B, Lanz D, Pearson R, Spies R. Factors in standardizing automated cholinesterase assays. J Toxicol Environ Health. 1996 Jun 7; 48(2):187-95.
    View PubMed
  71. McKinzie S, Tyce GM, Brimijoin S. Lowered norepinephrine turnover as a sign of impaired ganglionic transmission after preganglionic lesioning by acetylcholinesterase antibodies. J Pharmacol Exp Ther. 1996 May; 277(2):817-22.
    View PubMed
  72. Brimijoin S, Hammond P. Transient expression of acetylcholinesterase mRNA and enzyme activity in developing rat thalamus studied by quantitative histochemistry and in situ hybridization. Neurosci. 1996; 71:555-565.
  73. Carmichael SW, Brimijoin WS. Looking at slow axonal transport. Microscopy Today. 1996; 96(9):3.
  74. Holgert H, Åman K, Cozzari C, Hartman BK, Brimijoin S, Emson P, Goldstein M, Hökfelt T. The cholinergic innervation of the adrenal gland and its relation to enkephalin and nitric oxide synthase. Neuroreport. 1995 Dec 15; 6(18):2576-80.
    View PubMed
  75. Brimijoin WS. Using antibodies to unwire the sympathetic nervous system. News Physiol Sci. 1995 Jun; 10:101-106.
  76. Bruss M, Hammermann R, Brimijoin S, Bonisch H. Antipeptide antibodies confirm the topology of the human norepinephrine transporter. J Biol Chem. 1995 Apr 21; 270(16):9197-201.
    View PubMed
  77. Russell JW, Windebank AJ, McNiven MA, Brat DJ, Brimijoin WS. Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Res. 1995 Apr 10; 676(2):258-67.
    View PubMed
  78. Li W, Ochalski PA, Brimijoin S, Jordan LM, Nagy JI. C-terminals on motoneurons: electron microscope localization of cholinergic markers in adult rats and antibody-induced depletion in neonates. Neuroscience. 1995 Apr; 65(3):879-91.
    View PubMed
  79. Chiappa S, Padilla S, Koenigsberger C, Moser V, Brimijoin S. Slow accumulation of acetylcholinesterase in rat brain during enzyme inhibition by repeated dosing with chlorpyrifos. Biochem Pharmacol. 1995 Mar 30; 49(7):955-63.
    View PubMed
  80. Brimijoin S, Dagerlind A, Rao R, McKinzie S, Hammond P. Accumulation of enkephalin, proenkephalin mRNA, and neuropeptide Y in immunologically denervated rat adrenal glands: evidence for divergent peptide regulation. J Neurochem. 1995 Mar; 64(3):1281-7.
    View PubMed
  81. Rao R, Brimijoin S. Reverse transcriptase-polymerase chain reaction assay for acetylcholinesterase mRNA in rat brain. Neurochem Res. 1995 Feb; 20(2):129-35.
    View PubMed
  82. Hammond P, Rao R, Koenigsberger C, Brimijoin S. Regional variation in expression of acetylcholinesterase mRNA in adult rat brain analyzed by in situ hybridization. Proc Natl Acad Sci U S A. 1994 Nov 8; 91(23):10933-7.
    View PubMed
  83. Dagerlind A, Pelto-Huikko M, Lundberg JM, Ubink R, Verhofstad A, Brimijoin S, Hokfelt T. Immunologically induced sympathectomy of preganglionic nerves by antibodies against acetylcholinesterase: increased levels of peptides and their messenger RNAs in rat adrenal chromaffin cells. Neuroscience. 1994 Sep; 62(1):217-39.
    View PubMed
  84. Mesulam MM, Brimijoin S, Geula C. Neurofibrillary tangles have no obligatory predilection for acetylcholinesterase-rich neurons. Neurobiol Aging. 1994 Sep-Oct; 15(5):615-9.
    View PubMed
  85. Brimijoin S, Hammond P, Khraibi AA, Tyce GM. Catecholamine release and excretion in rats with immunologically induced preganglionic sympathectomy. J Neurochem. 1994 Jun; 62(6):2195-204.
    View PubMed
  86. Dagerlind A, Zhang X, Brimijoin S, Lindh B, Hokfelt T. Effects of preganglionic sympathectomy on peptides in the rat superior cervical ganglion. Neuroreport. 1994 Apr 14; 5(8):909-12.
    View PubMed
  87. Oka N, Brimijoin S. Altered spectrum of retrogradely transported axonal proteins in P-bromophylacetylurea neuropathy. Neurochem Res. 1993 Jun; 18:675-680.
    View PubMed
  88. Dagerlind A, Brimijoin S, Goldstein M, Hokfelt T. Effects of antibodies against acetylcholinesterase on the expression of peptides and catecholamine synthesizing enzymes in the rat adrenal gland. Neuroscience. 1993 Jun; 54:1079-1090.
    View PubMed
  89. Brat DJ, Brimijoin S. Acrylamide and glycidamide impair neurite outgrowth in differentiating N1E.115 neuroblastoma without disturbing rapid bidirectional transport of organelles observed by video microscopy. J Neurochem. 1993 Jun; 60(6):2145-52.
    View PubMed
  90. Brimijoin S, Moser V, Hammond P, Oka N, Lennon VA. Death of intermediolateral spinal cord neurons follows selective, complement-mediated destruction of peripheral preganglionic sympathetic terminals by acetylcholinesterase antibodies. Neuroscience. 1993 May; 54(1):201-23.
    View PubMed
  91. Rakonczay Z, Hammond P, Brimijoin S. Lesion of central cholinergic systems by systemically administered acetylcholinesterase antibodies in newborn rats. Neuroscience. 1993 May; 54(1):225-38.
    View PubMed
  92. Brat DJ, Brimijoin S. A paradigm for examining toxicant effects on viability, structure, and axonal transport of neurons in culture. Mol Neurobiol. 1992 Summer-Fall; 6(2-3):125-35.
    View PubMed
  93. Brat DJ, Windebank AJ, Brimijoin S. Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther. 1992 May; 261(2):803-10.
    View PubMed
  94. Oka N, Brimijoin WS. Tubulomembranous lesions in p-bromophenylacetylurea neuropathy reflect local stasis of fast axonal transport: evidence from electron microscopic autoradiography. Mayo Clin Proc. 1992 Apr; 67(4):341-8.
    View PubMed
  95. Padilla S, Moser VC, Pope CN, Brimijoin WS. Paraoxon toxicity is not potentiated by prior reduction in blood acetylcholinesterase. Toxicol Appl Pharmacol. 1992; 117:110-115.
    View PubMed
  96. Bean AJ, Xu Z, Chai SY, Brimijoin S, Hokfelt T. Effect of intracerebral injection of monoclonal acetylcholinesterase antibodies on cholinergic nerve terminals in the rat central nervous system. Neurosci Lett. 1991 Nov 25; 133(1):145-9.
    View PubMed
  97. Mesulam MM, Geula C, Cosgrove R, Mash D, Brimijoin S. Immunocytochemical demonstration of axonal and perikaryl in human cerebral cortex. Brain Res. 1991 Jan 25; 539:233-238.
    View PubMed
  98. Brimijoin S, Lennon VA. Selective destruction of preganglionic sympathetic nerves by antibodies to acetylcholinesterase. J Neural Transm Suppl. 1991; 34:139-45.
    View PubMed
  99. Brimijoin S, Lennon VA. Autoimmune preganglionic sympathectomy induced by acetylcholinesterase antibodies. Proc Natl Acad Sci U S A. 1990 Dec; 87(24):9630-4.
    View PubMed
  100. Oka N, Brimijoin S. Premature onset of fast axonal transport in bromophenylacetylurea neuropathy: an electrophoretic analysis of proteins exported into motor nerve. Brain Res. 1990 Feb 12; 509(1):107-10.
    View PubMed
  101. Brimijoin S, Balm M, Hammond P, Lennon VA. Selective complexing of acetylcholinesterase in brain by intravenously administered monoclonal antibody. J Neurochem. 1990 Jan; 54(1):236-41.
    View PubMed
  102. Studelska DR, Brimijoin S. Partial isolation of two classes of dopamine beta-hydroxylase-containing particles undergoing rapid axonal transport in rat sciatic nerve. J Neurochem. 1989 Aug; 53(2):622-31.
    View PubMed
  103. Brimijoin S, Hammond P. Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay. J Neurochem. 1988 Oct; 51:1227-1231.
    View PubMed
  104. Hammond P, Brimijoin S. Acetylcholinesterase in Huntington's and Alzheimer's diseases: simultaneous enzyme assay and immunoassay of multiple brain regions. J Neurochem. 1988 Apr; 50(4):1111-6.
    View PubMed
  105. Nelson DK, Service JE, Studelska DR, Brimijoin S, Go VL. Gastrointestinal neuropeptide concentrations following guanethidine sympathectomy. J Auton Nerv Syst. 1988 Apr; 22(3):203-10.
    View PubMed
  106. Nagata H, Brimijoin S, Low P, Schmelzer JD. Slow axonal transport in experimental hypoxia and in neuropathy induced by p-bromophenylacetylurea. Brain Res. 1987 Oct 6; 422(2):319-26.
    View PubMed
  107. Brimijoin S, Hammond P, Rakonczay Z. Two-site immunoassay for acetylcholinesterase in brain, nerve, and muscle. J Neurochem. 1987 Aug; 49(2):555-62.
    View PubMed
  108. Brimijoin S, Rakonczay ZR, Hammond P. Immunoassay of acetylcholinesterase. Fed Proc. 1987 Jun; 46(8):2557-62.
    View PubMed
  109. Pfeiffer GL, Brimijoin WS, Studelska DR, Carmichael SW. Electron microscopy of isolated mitochondrion-chromaffin vesicle complexes. Z Mikrosk Anat Forsch. 1987; 101(4):567-76.
    View PubMed
  110. Brimijoin S, Rakonczay Z, Mintz K. Immunochemistry of mammalian cholinesterases. Fed Proc. 1986 Dec; 45(13):2960-4.
    View PubMed
  111. Nagata H, Brimijoin S. Neurotoxicity of halogenated phenylacetylureas is linked to abnormal onset of rapid axonal transport. Brain Res. 1986 Oct 15; 385(1):136-42.
    View PubMed
  112. Nagata H, Brimijoin S. Axonal transport in the motor neurons of rats with neuropathy induced by p-bromophenylacetylurea. Ann Neurol. 1986 May; 19(5):458-64.
    View PubMed
  113. Rakonczay Z, Brimijoin S. Monoclonal antibodies to rat brain acetylcholinesterase: comparative affinity for soluble and membrane-associated enzyme and for enzyme from different vertebrate species. J Neurochem. 1986 Jan; 46(1):280-7.
    View PubMed
  114. Brimijoin S, Hammond P, Petitt R. Paroxysmal nocturnal hemoglobinuria: Red cell acetylcholinesterase deficit analyzed by immunoassay and fluorescence-activated sorting. Mayo Clinic Proc. 1986; 61:522-529.
  115. Brimijoin S, Rakonczay Z. Immunology and molecular biology of the cholinesterases: current results and prospects. Int Rev Neurobiol. 1986; 28:363-410.
    View PubMed
  116. Brimijoin S, Mintz KP, Prendergast FG. An inhibitory monoclonal antibody to rabbit brain acetylcholinesterase. Studies on interaction with the enzyme. Mol Pharmacol. 1985 Dec; 28(6):539-45.
    View PubMed
  117. Rakonczay Z, Brimijoin S. Immunochemical differences among molecular forms of acetylcholinesterase in brain and blood. Biochim Biophys Acta. 1985 Nov 29; 832(2):127-34.
    View PubMed
  118. Mintz KP, Brimijoin S. Monoclonal antibodies to rabbit brain acetylcholinesterase: selective enzyme inhibition, differential affinity for enzyme forms, and cross- reactivity with other mammalian cholinesterases. J Neurochem. 1985 Jul; 45(1):284-92.
    View PubMed
  119. Brimijoin S, Mintz KP. Human acetylcholinesterase. Immunochemical studies with monoclonal antibodies. Biochim Biophys Acta. 1985 Apr 29; 828(3):290-7.
    View PubMed
  120. Low PA, Ward K, Schmelzer JD, Brimijoin S. Ischemic conduction failure and energy metabolism in experimental diabetic neuropathy. Am J Physiol. 1985 Apr; 248(4 Pt 1):E457-62.
    View PubMed
  121. Studelska DR, Campbell NR, Brimijoin WS. Catecholamine binding by adrenal medullary protein can interfere with a sensitive radioenzymatic assay for norepinephrine. Life Sci. 1985 Mar 4; 36(9):881-7.
    View PubMed
  122. Brimijoin WS, Hammond PI. Acrylamide neuropathy in the rat: effects on energy metabolism in sciatic nerve. Mayo Clin Proc. 1985 Jan; 60(1):3-8.
    View PubMed
  123. Mintz KP, Brimijoin S. Two-step immunoaffinity purification of acetylcholinesterase from rabbit brain. J Neurochem. 1985 Jan; 44(1):225-32.
    View PubMed
  124. Rakonczay Z, Brimijoin S. Monoclonal antibodies to human brain acetylcholinesterase: properties and applications. Cell Mol Neurobiol. 1985; 8:85-93.
  125. Brimijoin S, Mintz KP. Unimpaired energy metabolism in experimental neuropathy induced by P-bromophenylacetylurea. Muscle Nerve. 1984 Nov/Dec; 7:725-732.
    View PubMed
  126. Mintz KP, Weinshilboum RM, Brimijoin WS. Evolution of butyrylcholinesterase in higher primates: an immunochemical study. Comp Biochem Physiol C. 1984; 79(1):35-7.
    View PubMed
  127. Brimijoin S, Mintz KP, Alley MC. Production and characterization of separate monoclonal antibodies to human acetylcholinesterase and butyrylcholinesterase. Mol Pharmacol. 1983 Nov; 24(3):513-20.
    View PubMed
  128. Litchy WJ, Brimijoin S. Concentration dependence of rapid axonal transport: a study of the transport kinetics of [35S]methionine-labeled protein in postganglionic sympathetic fibers of the bullfrog. J Neurosci. 1983 Oct; 3(10):2075-82.
    View PubMed
  129. Dyck PJ, Mellinger JF, Reagan TJ, Horowitz SJ, McDonald JW, Litchy WJ, Daube JR, Fealey RD, Go VLW, Kao PC, Brimijoin WS, Lambert EH. Not 'indifference to pain', but varieties of hereditary, sensory, and autonomic neuropathy. Brain. 1983 Jun; 106(PART II):373-390.
    View PubMed
  130. Edwards JA, Brimijoin S. Effects of hypophysectomy on acetylcholinesterase and butyrylcholinesterase in the rat. Biochem Pharmacol. 1983 Apr 1; 32(7):1183-9.
    View PubMed
  131. Brimijoin S, Mintz KP, Prendergast FG. Dansylarginine N-(3-ethyl-1.5-pentanediyl)amide. A potent and selective fluorescent inhibitor of butyrylcholinesterase. Biochem Pharmacol. 1983 Feb 15; 32(4):699-706.
    View PubMed
  132. Edwards JA, Brimijoin S. Thermal inactivation of the molecular forms of acetylcholinesterase and butyrylcholinesterase. Biochim Biophys Acta. 1983 Feb 15; 742(3):509-16.
    View PubMed
  133. Jakobsen J, Brimijoin S, Sidenius P. Axonal transport in neuropathy. Muscle Nerve. 1983 Feb; 6(2):164-6.
    View PubMed
  134. Brimijoin S. Molecular forms of acetylcholinesterase in brain, nerve and muscle: nature, localization and dynamics. Prog Neurobiol. 1983; 21(4):291-322.
    View PubMed
  135. Brimijoin WS. Abnormalities of axonal transport: are they a cause of peripheral nerve disease? Mayo Clin Proc. 1982 Nov; 57(11):707-14.
    View PubMed
  136. Edwards JA, Brimijoin S. Divergent regulation of acetylcholinesterase and butyrylcholinesterase in tissues of the rat. J Neurochem. 1982 May; 38(5):1393-403.
    View PubMed
  137. Brimijoin S, Schreiber PA. Reduced axonal transport of 10S acetylcholinesterase in dystrophic mice. Muscle Nerve. 1982 May-Jun; 5(5):405-10.
    View PubMed
  138. Brimijoin S. Microtubules and the capacity of the system for rapid axonal transport. Fed Proc. 1982 May; 41(7):2312-6.
    View PubMed
  139. Carter J, Lennon VA, Schreiber P, Brimijoin S. Content and release of acetylcholinesterase in skeletal muscle of rats with experimental autoimmune myasthenia gravis. Exp Neurol. 1982 Feb; 75(2):490-500.
    View PubMed
  140. Brimijoin S, Carter J. Turnover of the molecular forms of acetylcholinesterase in the rat diaphragm. J Neurochem. 1982 Feb; 38(2):588-90.
    View PubMed
  141. Jakobsen J, Lambert EH, Carlson G, Brimijoin S. Clinical and electrophysiological characteristics of the experimental neuropathy caused by p-bromophenylacetylurea. Exp Neurol. 1982 Jan; 75(1):158-72.
    View PubMed
  142. Brimijoin S, Carlson G, Nguyen NN, Jakobsen J. Analogs of p-bromophenylacetylurea: a structure activity study of their neurotoxicity in rats. Muscle Nerve. 1982; 5(9S):S122-6.
    View PubMed
  143. Jakobsen J, Brimijoin S. Axonal transport of enzymes and labeled proteins in experimental axonopathy induced by p-bromophenylacetylurea. Brain Res. 1981 Dec 14; 229(1):103-22.
    View PubMed
  144. Skau KA, Brimijoin S. Abnormal distribution of skeletal muscle acetylcholinesterase molecular forms in dystrophic mice. Exp Neurol. 1981 Oct; 74(1):111-21.
    View PubMed
  145. Jakobsen J, Brimijoin S, Skau K, Sidenius P, Wells D. Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes. 1981 Oct; 30(10):797-803.
    View PubMed
  146. Lundberg JM, Fahrenkrug J, Brimijoin S. Characteristics of the axonal transport of vasoactive intestinal polypeptide (VIP) in nerves of the cat. Acta Physiol Scand. 1981 Aug; 112(4):427-36.
    View PubMed
  147. Cater JL, Brimijoin S. Effects of acute and chronic denervation on release of acetylcholinesterase and its molecular forms in rat diaphragms. J Neurochem. 1981 Mar; 36(3):1018-25.
    View PubMed
  148. Evans BA, Yao JK, Holman RT, Brimijoin WS, Lambert EH, Dyck PJ. Structural and biochemical effects of essential fatty acid deficiency on peripheral nerve. J Neuropathol Exp Neurol. 1980 Nov; 39(6):683-91.
    View PubMed
  149. Skau KA, Brimijoin S. Multiple molecular forms of acetylcholinesterase in rat vagus nerve, smooth muscle, and heart. J Neurochem. 1980 Nov; 35(5):1151-4.
    View PubMed
  150. Brimijoin S, Lundberg JM, Brodin E, Hokfelt T, Nilsson G. Axonal transport of substance P in the vagus and sciatic nerves of the guinea pig. Brain Res. 1980 Jun 9; 191(2):443-57.
    View PubMed
  151. Lundberg JM, Hokfelt T, Anggard A, Uvnas-Wallensten K, Brimijoin S, Brodin E, Fahrenkrug J. Peripheral peptide neurons: distribution, axonal transport, and some aspects on possible function. Adv Biochem Psychopharmacol. 1980; 22:25-36.
    View PubMed
  152. Brimijoin S, Dyck PJ. Axonal transport of dopamine-beta-hydroxylase and acetylcholinesterase in human peripheral neuropathy. Exp Neurol. 1979 Dec; 66(3):467-78.
    View PubMed
  153. Dyck PJ, Carney JA, Sizemore GW, Okazaki H, Brimijoin WS, Lambert EH. Multiple endocrine neoplasia, type 2b: phenotype recognition; neurological features and their pathological basis. Ann Neurol. 1979 Oct; 6(4):302-14.
    View PubMed
  154. Brimijoin S. On the kinetics and maximal capacity of the system for rapid axonal transport in mammalian neurones. J Physiol (Lond) 1979 Jul; 292:325-37.
    View PubMed
  155. Brimijoin S. Axonal transport and subcellular distribution of molecular forms of acetylcholinesterase in rabbit sciatic nerve. Mol Pharmacol. 1979 May; 15(3):641-8.
    View PubMed
  156. Brimijoin S, Olsen J, Rosenson R. Comparison of the temperature-dependence of rapid axonal transport and microtubules in nerves of the rabbit and bullfrog. J Physiol (Lond) 1979 Feb; 287:303-14.
    View PubMed
  157. Starkey RR, Brimijoin S. Stop-flow analysis of the axonal transport of dopa decarboxylase (EC 4.1.1.26) in rabbit sciatic nerves. J Neurochem. 1979 Feb; 32(2):437-41.
    View PubMed
  158. Brimijoin S, Wiermaa MJ. Rapid orthograde and retrograde axonal transport of acetylcholinesterase as characterized by the stop-flow technique. J Physiol (Lond) 1978 Dec; 285:129-42.
    View PubMed
  159. Brimijoin S, Skau K, Wiermaa MJ. On the origin and fate of external acetylcholinesterase in peripheral nerve. J Physiol (Lond) 1978 Dec; 285:143-58.
    View PubMed
  160. Skau KA, Brimijoin S. Release of acetylcholinesterase from rat hemidiaphragm preparations stimulated through the phrenic nerve. Nature. 1978 Sep 21; 275(5677):224-6.
    View PubMed
  161. Brimijoin S. A histofluorescence study of events accompanying accumulation and migration of norepinephrine within locally cooled nerves. J Neurobiol. 1977 May; 8(3):251-63.
    View PubMed
  162. Brimijoin S, Wiermaa MJ. Direct comparison of the rapid axonal transport of norepinephrine and dopamine-beta-hydroxylase activity. J Neurobiol. 1977 May; 8(3):239-50.
    View PubMed
  163. Brimijoin S, Wiermaa MJ. Rapid axonal transport of tyrosine hydroxylase in rabbit sciatic nerves. Brain Res. 1977 Jan 31; 121(1):77-96.
    View PubMed
  164. Ohnishi A, Schilling K, Brimijoin WS, Lambert EH, Fairbanks VF, Dyck PJ. Lead neuropathy: 1. Morphometry, nerve conduction, and choline acetyltransferase transport: new finding of endoneurial edema associated with segmental demyelination. J Neuropathol Exp Neurol. 1977; 36:499-518.
    View PubMed
  165. Cosens B, Thacker D, Brimijoin S. Temperature-dependence of rapid axonal transport in sympathetic nerves of the rabbit. J Neurobiol. 1976 Jul; 7(4):339-54.
    View PubMed
  166. Brimijoin S, Helland L. Rapid retrograde transport of dopamine-beta-hydroxylase as examined by the stop-flow technique. Brain Res. 1976 Feb 6; 102(2):217-28.
    View PubMed
  167. Brimijoin S. Cycloheximide alters axonal transport and subcellular distribution of dopamine-beta-hydroxylase activity. J Neurochem. 1976 Jan; 26(1):35-40.
    View PubMed
  168. Brimijoin S, Jablecki C. Reduced axonal transport of dopamine-beta-hydroxylase in dystrophic mice: evidence for abnormality of adrenergic nerve cells. Exp Neurol. 1976; 53:454-464.
    View PubMed
  169. Jablecki C, Brimijoin S. Axoplasmic transport of choline acetyltransferase activity in mice: effect of age and neurotomy. J Neurochem. 1975 Nov; 25(5):583-93.
    View PubMed
  170. Brimijoin S. Stop-flow: a new technique for measuring axonal transport, and its application to the transport of dopamine-beta-hydroxylase. J Neurobiol. 1975 Jul; 6(4):379-94.
    View PubMed
  171. Jablecki C, Brimijoin S. Reduced axoplasmic transport of choline acetyltransferase activity in dystrophic mice. Nature. 1974 Jul 12; 250(462):151-4.
    View PubMed
  172. Brimijoin S. Local changes in subcellular distribution of dopamine-beta-hydroxylase (EC 1.14.2.1) after blockade of axonal transport. J Neurochem. 1974 Mar; 22(3):347-53.
    View PubMed
  173. Brimijoin WS. Evidence that 6-hydroxydopamine decreases synthesis of dopamine-beta-hydroxylase in sympathetic ganglia. J Pharmacol Exp Ther. 1972 Nov; 183:298-306.
    View PubMed
  174. Brimijoin WS. Transport and turnover of dopamine-beta-hydroxylase (EC 1.14.2.1) in sympathetic nerves of the rat. J Neurochem. 1972 Sep; 19:2183-93.
    View PubMed
  175. Molinoff PB, Brimijoin WS, Axelrod J. Induction of dopamine-beta-hydroxylase and tyrosine hydroxylase in rat hearts and sympathetic ganglia. J Pharmacol Exp Ther. 1972 Jul; 182:116-29.
    View PubMed
  176. Silberstein SD, Lemberger L, Brimijoin WS, Molinoff PB. Induction of dopamine-beta-hydroxylase in rat superior cervical ganglia in organ culture. J Neurochem. 1972 Mar; 19:919-21.
    View PubMed
  177. Brimijoin S, Molinoff PB. Effects of 6-hydroxydopamine on the activity of tyrosine hydroxylase and dopamine- -hydroxylase in sympathetic ganglia of the rat. J Pharmacol Exp Ther. 1971 Sep; 178(3):417-24.
    View PubMed
  178. Brimijoin S, Trendelenburg U. Reserpine-induced release of norepinephrine from isolated spontaneously beating guinea-pig atria. J Pharmacol Exp Ther. 1971 Jan; 176(1):149-59.
    View PubMed
  179. Brimijoin S, Pluchino S, Trendelenburg U. On the mechanism of supersensitivity to norepinephrine in the denervated cat spleen. J Pharmacol Exp Ther. 1970 Nov; 175(2):503-13.
    View PubMed
  180. Molinoff PB, Brimijoin S, Weinshilboum R, Axelrod J. Neurally mediated increase in dopamine-beta-hydroxylase activity. Proc Natl Acad Sci U S A. 1970 Jun; 66(2):453-8.
    View PubMed